Amendment: SEC Form SC 13G/A filed by Day One Biopharmaceuticals Inc.

11/7/24 9:24:55 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $DAWN alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.1 DAY ONE BIOPHARMACEUTICALS INC COMMON STOCK Cusip #23954D109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #23954D109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 11,265,165 Item 6: 0 Item 7: 11,287,327 Item 8: 0 Item 9: 11,287,327 Item 11: 11.192% Item 12: HC Cusip #23954D109 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 11,287,327 Item 8: 0 Item 9: 11,287,327 Item 11: 11.192% Item 12: IN Item 1(a). Name of Issuer: DAY ONE BIOPHARMACEUTICALS INC Item 1(b). Address of Issuer's Principal Executive Offices: 2000 SIERRA POINT PARKWAY, SUITE 501 Brisbane, CA 94005 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 23954D109 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 11,287,327 (b) Percent of Class: 11.192% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 11,287,327 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of DAY ONE BIOPHARMACEUTICALS INC. No one other person's interest in the COMMON STOCK of DAY ONE BIOPHARMACEUTICALS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 6, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company BK Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 6, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of DAY ONE BIOPHARMACEUTICALS INC at October 31, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $DAWN alert in real time by email

Recent Analyst Ratings for

$DAWN

Date	Price Target	Rating	Analyst
8/19/2025	$25.00	Overweight	Piper Sandler
10/9/2024	$32.00 → $33.00	Buy	Needham
8/1/2024	$11.00 → $24.00	Underperform → Buy	BofA Securities
4/24/2024	$30.00 → $33.00	Buy	Needham
4/25/2023	$34.00 → $9.00	Buy → Underperform	BofA Securities
2/8/2023	$40.00	Overweight	CapitalOne
2/3/2023		Perform	Oppenheimer
12/15/2022	$35.00	Buy	H.C. Wainwright

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Day One Biopharmaceuticals Inc.

11/7/24 9:24:55 AM ET

$DAWN

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $DAWN alert in real time by email

Recent Analyst Ratings for

$DAWN

Date	Price Target	Rating	Analyst
8/19/2025	$25.00	Overweight	Piper Sandler
10/9/2024	$32.00 → $33.00	Buy	Needham
8/1/2024	$11.00 → $24.00	Underperform → Buy	BofA Securities
4/24/2024	$30.00 → $33.00	Buy	Needham
4/25/2023	$34.00 → $9.00	Buy → Underperform	BofA Securities
2/8/2023	$40.00	Overweight	CapitalOne
2/3/2023		Perform	Oppenheimer
12/15/2022	$35.00	Buy	H.C. Wainwright

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Day One Biopharmaceuticals Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$DAWN

Amendment: SEC Form SC 13G/A filed by Day One Biopharmaceuticals Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$DAWN

$DAWN
Insider Trading

Gen Counsel & Secretary Dubow Adam converted options into 12,087 shares and sold $38,503 worth of shares (4,319 units at $8.91), increasing direct ownership by 14% to 62,626 units (SEC Form 4)

COO and CFO York Charles N Ii converted options into 16,875 shares and sold $36,212 worth of shares (4,062 units at $8.91), increasing direct ownership by 5% to 294,715 units (SEC Form 4)

Chief Commercial Officer Merendino Lauren converted options into 10,536 shares and sold $33,216 worth of shares (3,726 units at $8.91), increasing direct ownership by 15% to 50,809 units (SEC Form 4)

$DAWN
Insider Purchases

Ai Day1 Llc bought $14,978,327 worth of shares (1,475,454 units at $10.15) (SEC Form 4)

$DAWN
FDA approvals

April 30, 2024 - FDA Roundup: April 30, 2024

April 26, 2024 - FDA Roundup: April 26, 2024

FDA Approval for OJEMDA issued to DAY ONE BIOPHARMACEUTICALS INC

$DAWN
Press Releases

$DAWN
Analyst Ratings

$DAWN
SEC Filings

Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference

Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases

Day One Announces New OJEMDA™ (tovorafenib) Data to be Presented in Oral Session at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting

Piper Sandler initiated coverage on Day One Biopharmaceuticals with a new price target

Needham reiterated coverage on Day One Biopharmaceuticals with a new price target

Day One Biopharmaceuticals upgraded by BofA Securities with a new price target

SEC Form 144 filed by Day One Biopharmaceuticals Inc.

SEC Form 144 filed by Day One Biopharmaceuticals Inc.

SEC Form SC TO-C filed by Day One Biopharmaceuticals Inc.

$DAWN
Leadership Updates

Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development

Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development

Day One Announces Two New Appointments to Board of Directors

$DAWN
Financials

Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases

Day One Reports Third Quarter 2025 Financial Results and Corporate Progress

Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025

$DAWN
Large Ownership Changes